Abstract:Given the aging populations in advanced countries globally, many pharmaceutical companies have focused on developing central nervous system (CNS) drugs. However, due to the blood-brain barrier, drugs do not easily reach the target area in the brain. Although conventional screening methods for drug discovery involve the measurement of (unbound fraction of drug) brain-to-plasma partition coefficients, it is difficult to consider non-equilibrium between plasma and brain compound concentration-time profiles. To truly understand the pharmacokinetics/pharmacodynamics of CNS drugs, compound concentration-time profiles in the brain are necessary; however, such analyses are costly, time consuming, and require a significant number of animals. Therefore, in this study, we attempted to develop an in silico prediction method that does not require a large amount of experimental data by combining modeling and simulation (M&S) with machine learning (ML). First, we constructed a hybrid model linking plasma concentration-time profile to the brain compartment that takes into account the transit time and brain distribution of each compound. Using mouse plasma and brain time experimental values for 103 compounds, we determined the brain kinetic parameters of the hybrid model for each compound; this case was defined as scenario I (a positive control experiment) and included the full brain concentration-time profile data. Next, we built an ML model using chemical structure descriptors as explanatory variables and rate parameters as the target variable, and we then input the predicted values from 5-fold cross-validation (CV) into the hybrid model; this case was defined as scenario II, in which no brain compound concentration-time profile data exist. Finally, for scenario III, assuming that the brain concentration is obtained at only one time point, we used the brain kinetic parameters from the result of the 5-fold CV in scenario II as the initial values for the hybrid model and performed parameter re-fitting against the observed brain concentration at that time point. As a result, the RMSE/R2-values of the brain compound concentration-time profiles over time were 0.445/0.517 in scenario II and 0.246/0.805 in scenario III, indicating the method provides high accuracy and suggesting that it is a practical method for predicting brain compound concentration-time profiles.

Evaluation of Cerebrospinal Fluid Concentration and Plasma Free Concentration As a Surrogate Measurement for Brain Free Concentration

Unbound Drug Concentration in Brain Homogenate and Cerebral Spinal Fluid at Steady State as a Surrogate for Unbound Concentration in Brain Interstitial Fluid

Quantitative Investigation of the Brain-to-Cerebrospinal Fluid Unbound Drug Concentration Ratio under Steady-State Conditions in Rats Using a Pharmacokinetic Model and Scaling Factors for Active Efflux Transporters

Use of a Physiologically Based Pharmacokinetic Model to Study the Time to Reach Brain Equilibrium: an Experimental Analysis of the Role of Blood-Brain Barrier Permeability, Plasma Protein Binding, and Brain Tissue Binding

In Silico Modeling on ADME Properties of Natural Products: Classification Models for Blood-Brain Barrier Permeability, Its Application to Traditional Chinese Medicine and in Vitro Experimental Validation

Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios

Unbound Brain Concentration Determines Receptor Occupancy: A Correlation of Drug Concentration and Brain Serotonin and Dopamine Reuptake Transporter Occupancy for Eighteen Compounds in Rats

Limitations of Microdialysis in Measuring Unbound Drug Concentrations in the Brain

Applicability of Free Drug Hypothesis to Drugs with Good Membrane Permeability That Are Not Efflux Transporter Substrates: A Microdialysis Study in Rats

Experimental and Computational Methods to Assess Central Nervous System Penetration of Small Molecules

Physiologically Based Pharmacokinetic Model of Brain Delivery of Plasma Protein Bound Drugs

Application of a new MDCKII-MDR1 cell model to measure the extent of drug distribution in vitro at equilibrium for prediction of in vivo unbound brain-to-plasma drug distribution

A Computational Physics-based Approach to Predict Unbound Brain-to-Plasma Partition Coefficient, Kp,uu

Age dependent contribution of entry via the CSF to the overall brain entry of small and large hydrophilic markers

A practical in silico method for predicting compound brain concentration-time profiles: combination of PK modeling and machine learning

Brain endothelial permeability, transport, and flow assessed over 10 orders of magnitude using the in situ brain perfusion technique

A Semi-Physiological Three-Compartment Model Describes Brain Uptake Clearance and Efflux of Sucrose and Mannitol after IV Injection in Awake Mice

Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain—a Game Changing Parameter for CNS Drug Discovery and Development

A novel method to calculate the extent and amount of drug transported into CSF after intranasal administration.

Use of the Cassette-Dosing Approach to Assess Brain Penetration in Drug Discovery.

Efficient Brain Uptake of Piperine and Its Pharmacokinetics Characterization after Oral Administration